Authors
Latest:
Genetic Counseling for Ovarian CancerJubilee Brown, MD, obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.
Latest:
Dr. Moul Discusses Immunotherapy in Prostate CancerJudd W. Moul, MD, urologic oncologist, Duke Medicine, discusses the impact of immunotherapy in prostate cancer.
Latest:
Breast Cancer Pain ManagementJudith Paice, PhD, RN, Robert H. Lurie Comprehensive Cancer Center, discusses the current pain management for patients with breast cancer.
Latest:
Dr. Judy Boughey on Neoadjuvant Endocrine Therapy in Breast CancerBoughey says an ongoing national clinical trial is looking at patients with ER+ breast cancer and treating them with neoadjuvant endocrine therapy.
Latest:
Dr. Judy Boughey on the Safety of Nipple-Sparing MastectomiesDr. Judy C. Boughey talks about a study examining all patients at Mayo Clinic that underwent a nipple-sparing mastectomy for breast cancer and comparing those with positive lymph nodes to those with negative lymph nodes.
Latest:
Phase II Results of the GEOMETRY Mono-1 Study in NSCLCJuergen Wolf, MD, medical director, Center for Integrated Oncology (CIO) at the University Hospital Cologne, discusses the phase II findings of the GEOMETRY mono-1 study in patients with MET exon 14-mutated advanced non-small cell lung cancer.
Latest:
Identifying Characteristics of Ovarian Cancer, Other Tumor SubtypesJulia Elvin, MD, PhD, vice president and senior associate medical director, Foundation Medicine, discusses a study that explored the different characteristics of subtypes of ovarian cancer, peritoneal tumors, and fallopian tube tumors.
Latest:
A Study of Brain Radiotherapy With Lapatinib in HER2+ Breast CancerJulia White, MD, professor of Radiation Oncology, Ohio State University, discusses a phase II study of whole brain radiotherapy with concurrent lapatinib in patients with brain metasteses from HER2-positive breast cancer.
Latest:
The DUO Trial: IPI-145 vs Ofatumumab in Relapsed or Refractory CLL or SLLJulian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale behind the DUO trial.
Latest:
Phase 3 Trial Investigates T-DM1 and Pertuzumab in HER2+ Breast CancerJulie Gralow, MD, discusses the primary analysis of trastuzumab emtansine plus pertuzumab versus trastuzumab, pertuzumab, and taxane, after anthracyclines as adjuvant therapy in patients with high-risk HER2-positive early breast cancer in the of the KAITLIN study.
Latest:
Targeted/Chemo Combo Effective in Preclinical pNETs StudyCombining the chemotherapy streptozotocin with various mTOR inhibitors was found to effectively target tumors in preclinical studies for pancreatic neuroendocrine tumors (pNETs).
Latest:
Combining New Therapies and MRD Approaches Across LymphomasJulie Vose, MD, discusses the exciting developments across lymphomas.
Latest:
Getting Genetic Testing to Those Who Need ItJulie Nangia, MD, assistant professor of Medicine, Baylor College of Medicine, discusses getting genetic testing for patients. While the NCCN has guidelines of who should be tested, it may also be possible for physicians to write a letter of medical necessity for other people, such as Ashkenazi Jewish women, who have higher rates of BRCA mutations.
Latest:
Sequencing Immunotherapy in Biomarker-Driven Advanced NSCLCJulie Renee Brahmer, MD, MSc, discusses the issues with using tyrosine kinase inhibitors and immunotherapy in patients with locally advanced non–small cell lung cancer.
Latest:
Future Research Into Bisphosphonates in Breast CancerJulie R. Gralow, MD, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Care Center, University of Washington School of Medicine, discusses future research into bisphosphonates in breast cancer.
Latest:
GEOMETRY Study Confirms Importance of Testing for METex14 Alterations in Advanced NSCLCJurgen Wolf, MD, discusses the importance of broad genomic testing to identify alterations in patients with advanced non–small cell lung cancer (NSCLC). By identifying molecular alterations and driver mutations early on, patients can receive matched targeted therapies at a time in the course of disease when the treatments would have the greatest impact.
Latest:
Checkpoint Inhibitors Advance Standard of Care for Non-Small Cell Lung CancerJustin F. Gainor, MD, discusses the latest advancements with immune checkpoint inhibitors for the treatment of patients with non—small cell lung cancer.
Latest:
Exploring a Novel BTK Degrader and Current Options for CLLJustin Taylor, MD, discusses the treatment landscape for chronic lymphocytic leukemia and background on his early research assessing NX-2127 for this patient population.
Latest:
NSCLC: Factors in Selecting 2L Therapy After Progression on 1L ALK TKIExpert perspectives on factors that aid in the selection of optimal therapy for patients with relapsed/refractory ALK+ non–small cell lung cancer.
Latest:
NSCLC: Selecting a Frontline ALK-Targeted TKI TherapyA panel of experts considers which factors best inform selection of first-line ALK TKI therapy in patients with non–small cell lung cancer.
Latest:
Expert Addresses Sequencing Challenges in HCCKabir Mody, MD, discusses the importance of understanding sequencing in patients with hepatocellular carcinoma.
Latest:
Advances Changing the Treatment Landscape of AMLKamal Menghrajani, MD, a hematologist/oncologist at Memorial Sloan Kettering Cancer Center, discusses the latest advancement in the research of acute myeloid leukemia. After treating this disease the same way with traditional chemotherapy for over 40 years, researchers have finally come to an understanding of what is happening in the AML cells, leading to a more precise treatment of these patients.
Latest:
Researchers Analyze Karyotype Complexity and Prognosis in Acute Myeloid LeukemiaDiagnosis of acute myeloid leukemia (AML) is pivoted around cytogenetic analysis of patient bone marrow or peripheral blood cultures. The World Health Organization classification of tumors of the hematopoietic and lymphoid tissues is based on cytogenetic features along with other clinical, morphological, and immunophenotypic characteristics.
Latest:
Age-Related Recommendations in CLL TherapyWhen treatment decisions are being made regarding chronic lymphocytic leukemia (CLL), patient age should be an important factor. CLL is a disease of the elderly, with more than 40% of all patients >75 years.
